首页> 外文OA文献 >330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA

【2h】

330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA

机译：330完整的外科细胞渗透仍然是在PRCA1 / 2种系脉冲患者中实现晚期卵巢癌患者的更好的存活结果，仍然是PRCA1 / 2种系脉冲抑制剂时代

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mohamed Otify; Alexandros Laios; Hannah Elkadi; Angelika Kaufmann; Sarika Munot; George Theophilou; Amudha Thangavelu; David Nugent; Tim Broadhead; Richard Hutson; Diderick De Jong;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium [J] . Dimitrova Desislava, Ruscito Ilary, Olek Sven, Tumour biology : . 2016,第9期

机译：BRCA1基因外显子11的种系突变与原发性卵巢癌患者的铂应答无关，也没有生存优势：了解最大的人类外显子之一的临床重要性。肿瘤库卵巢癌（TOC）联盟的研究
2. PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2-ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS [J] . Goncalves Anthony, Quek Ruben G. W., Bhattacharyya Helen, The Breast : . 2019,第Suppla2期

机译：患者（PTS）患者（PTS）患者（PTS）患者（ABC）接受Talazoparib（TALA）VS Physisian的选择化疗（PCT）：专注于Hotmaca Germline BRCA1和BRCA2突变（GBRCA1 / 2M）亚组
3. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety [J] . Matulonis U. A., Penson R. T., Domchek S. M., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第6期

机译：Olaparib单药治疗晚期复发性卵巢癌和生殖系BRCA1 / 2突变的患者：疗效和安全性的多研究分析
4. Surgical Cytoreduction Could Improve the Effects of Chemotherapy After Operation and Maintain the QOL of Patients with Advanced Gastric Cancer [C] . A. Ishiguro, M. Munakata, Y. Sakat International Gastric Cancer Congress . 2005

机译：手术细胞凝固可以改善化疗后的疗法疗法，并维持晚期胃癌患者的QoL
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. Impact of Operative Start Time on Surgical Outcomes in Patients Undergoing Primary Cytoreduction for Advanced Ovarian Cancer [O] . Edward J. Tanner, Kara C. Long, Qin Zhou, -1

机译：手术开始时间对手术结果的影响在透析患者主要细胞减灭术的晚期卵巢癌
7. 270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy [O] . I Akaev, C Chau, N Dabab, 2019

机译：270大型单现场机构检测对体细胞和种系的一致性经验，BRCA1 / 2卵巢癌患者的致病性突变有资格获得PARP抑制剂治疗

330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA

著录项

引文网络

相似文献

相关主题

期刊订阅